IBIO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 21:42):

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States...

Stats
Dagens volum	138 632
Gjennomsnittsvolum	3.96M
Markedsverdi	15.68M
EPS	$0 ( 2024-02-13 )
Neste inntjeningsdato	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0150 (0.81%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Duran Felipe	Buy	35 800	Stock Option (right to buy)
2023-11-01	Brenner Martin	Sell	4 881	Common Stock
2023-10-03	Brenner Martin	Sell	5 267	Common Stock
2023-10-02	Brenner Martin	Sell	4 215	Common Stock
2023-08-28	Brenner Martin	Sell	5 011	Common Stock

INSIDER POWER
85.79
Last 90 transactions
Buy: 50 021 245 \| Sell: 29 398 433

Volum Korrelasjon

Lang: 0.14 (neutral)

Kort: -0.66 (moderate negative)

Signal:(45.046) Neutral

Ibio Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ibio Inc Korrelasjon - Valuta/Råvare

0.79
( moderate )

0.87
( strong )

0.51
( weak )

-0.54
( weak negative )

-0.92
( very strong negative )

Ibio Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2023
Omsetning:	$0
Bruttogevinst:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2022
Omsetning:	$2.38M
Bruttogevinst:	$2.17M (90.94 %)
EPS:	$-2 924.26

FY	2021
Omsetning:	$2.37M
Bruttogevinst:	$909 000 (38.34 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Ibio Inc

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.